Lazard Asset Management LLC Has $250,000 Stock Holdings in Evolent Health, Inc $EVH

Lazard Asset Management LLC decreased its holdings in shares of Evolent Health, Inc (NYSE:EVH) by 68.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 109,623 shares of the technology company’s stock after selling 239,799 shares during the quarter. Lazard Asset Management LLC’s holdings in Evolent Health were worth $250,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Evolent Health by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock worth $1,217,000 after buying an additional 3,572 shares in the last quarter. CIBC Private Wealth Group LLC boosted its holdings in Evolent Health by 4,000.0% in the third quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the last quarter. Strs Ohio acquired a new stake in Evolent Health in the first quarter worth about $47,000. Headlands Technologies LLC bought a new stake in Evolent Health during the 2nd quarter worth about $58,000. Finally, Osaic Holdings Inc. lifted its position in Evolent Health by 99.2% during the 2nd quarter. Osaic Holdings Inc. now owns 11,119 shares of the technology company’s stock valued at $125,000 after purchasing an additional 5,537 shares during the period.

Evolent Health Stock Performance

EVH opened at $3.96 on Friday. The business’s 50-day moving average price is $4.75 and its two-hundred day moving average price is $3.72. Evolent Health, Inc has a 1 year low of $2.10 and a 1 year high of $10.08. The company has a market capitalization of $445.20 million, a price-to-earnings ratio of -0.87 and a beta of 0.79. The company has a debt-to-equity ratio of 2.46, a current ratio of 1.32 and a quick ratio of 1.32.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, August 6th. The technology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. Evolent Health had a negative return on equity of 3.94% and a negative net margin of 24.08%.The business had revenue of $484.50 million during the quarter, compared to the consensus estimate of $597.69 million. During the same period last year, the company earned ($0.10) earnings per share. Evolent Health’s quarterly revenue was up 46.9% on a year-over-year basis. Equities analysts expect that Evolent Health, Inc will post -0.16 EPS for the current fiscal year.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent reported second-quarter adjusted earnings of $0.02 per share, compared with analysts’ expectation of a $0.01 loss and a $0.10 loss in the year-ago quarter. Evolent Health Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue rose sharply year over year, with management emphasizing continued growth, improving profitability, and stronger cash flow. The earnings call also highlighted a bullish 2027 outlook, supporting the view that Evolent’s expansion is becoming more durable. Evolent Health Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.6 billion to $2.7 billion, above the roughly $2.5 billion consensus estimate. That outlook gives investors greater confidence in Evolent’s growth trajectory. Evolent Announces Second Quarter 2026 Results
• Neutral Sentiment: Despite the improved operating performance, Evolent remains unprofitable on a GAAP basis, with a negative net margin, and analysts still project a full-year loss. Execution against the new guidance will therefore remain important.
• Negative Sentiment: The company continues to carry elevated leverage, including a debt-to-equity ratio above 2, which could limit financial flexibility if growth or cash-flow improvements fall short.

Analyst Ratings Changes

EVH has been the subject of several analyst reports. TD Cowen lowered their price target on shares of Evolent Health from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Citigroup reiterated a “sell” rating and set a $6.75 target price (up from $5.50) on shares of Evolent Health in a research report on Thursday, July 23rd. Truist Financial lowered Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 price target on the stock. in a research report on Tuesday, June 30th. Canaccord Genuity Group lifted their price objective on Evolent Health from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Finally, Needham & Company LLC increased their target price on Evolent Health from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Evolent Health currently has a consensus rating of “Moderate Buy” and an average price target of $6.16.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.